Академический Документы
Профессиональный Документы
Культура Документы
Vaccines
for
Clinical Use
Dr.T.V.Rao MD
What is a “Vaccine”
The term vaccine
derives from Edward
Jenner's 1796 use of
the term cow pox (Latin)
variola vaccinæ,
adapted from the Latin
vaccīn-us, from vacca
cow), which, when
administered to
humans, provided them
protection against
smallpox
Vaccine- Definition
A vaccine is any preparation intended to
produce immunity to a disease by
stimulating the production of antibodies.
Vaccines include, for example,
suspensions of killed or attenuated
microorganisms, or products or derivatives
of microorganisms. The most common
method of administering vaccines is by
injection, but some are given by mouth or
nasal spray.
Dr Jenner and Cow Pox
THE MODERN SCIENCE OF
IMMUNOLOGY HAD ITS
BEGINNINGS IN 1798 , WHEN
THE ENGLISH PHYSICIAN
EDWARD JENNER PUBLISHED A
PAPER IN WHICH HE
MAINTAINED THAT PEOPLE
COULD BE PROTECTED FROM
THE DEADLY DISEASE
SMALLPOX BY THE PRICK OF A
NEEDLE DIPPED IN THE PUS
FROM A COWPOX BOIL .
Historical Picture of Vaccination
Vaccine stimulates Immune
System
A vaccine is a biological preparation that
improves immunity to a particular disease. A
vaccine typically contains an agent that
resembles a disease-causing microorganism,
and is often made from weakened or killed forms
of the microbe. The agent stimulates the body's
immune system to recognize the agent as
foreign, destroy it, and "remember" it, so that the
immune system can more easily recognize and
destroy any of these microorganisms that it later
encounters
Preparation of Vaccines
a. Liveattenuated organisms which have been passed
repeatedly in tissue culture or chick embryos so that
they have lost their capacity to cause disease, but
retained an ability to induce antibody response, such
as polio (Sabin), measles, rubella, mumps, yellow fever,
BCG, typhoid and plague.
b. Inactivated or killed organisms which have been killed
by heat or chemicals but retain and ability to induce
antibody response. They are generally safe but less
efficacious than live vaccines and require multiple
doses; e.g. polio (Salk), influenza, rabies and Japanese
encephalitis.
Preparation of Vaccines
c. Cellular fractions: usually polysaccharide fraction
of the cell wall of a disease causing organism,
such as pneumococcal pneumonia or
meningococcal meningitis
d. Recombinant vaccines: produced by methods in
which specific DNA sequences are inserted by
molecular engineering techniques, e.g. DNA
sequences spliced to vaccinia virus grown in cell
culture to produces an effective influenza vaccine,
and Hepatitis B vaccine by similar methods.
Passive Immunity
“Vaccination”
Toxoids or antisera: are modified toxins made non-toxic to
stimulate formation of an antitoxin, such as those produced to
protect against toxins of tetanus, diphtheria, botulism, gas
gangrene, snake and scorpion venom.
11 Developing Countries
10 Varicella
9 Haemophilus Influenzae
Measles Hepatitis B
8 Mumps
Rubella
7 DPT
6 Poliomyelitis
Hepatitis B**
5
Measles
1975
DPT 1980 1985 1990 1995 2000
Poliomyelitis
BCG
20%
ARI
Diarrhea
VPD
Perinatal
Other
20%
19%
13%
The Global Burden of Disease
Murray and Lopez, editors
Total - 12.8 million
New approved vaccines
A number of new vaccines with major
potential for controlling infectious diseases
have just been licensed or are at
advanced stages of development. Among
the illnesses targeted are rotavirus
diarrhoea, pneumococcal disease, and
cervical cancer (as caused by human
papillomavirus), which together kill more
than a million people each year, most of
them in developing countries.
Bacterial Meningitis kills several in
Developing world
Haemophilus influenzae type b (Hib)
30% -50% of bacterial meningitis
Pneumococcus
25- 35% of bacterial meningitis
Meningococcus
25 - 35% of bacterial meningitis (except
during epidemics)
Hib meningitis and pneumonia burden
Synthetic peptide
Naked DNA
Inactivated Virus
Live-attenuated
Virus
Live-vectored Vaccine
Challenges in HIV Vaccine Research
• Viral Genetic Diversity: HIV is not just one
specific virus.
• Immune Protection: We don’t know what
immune responses are needed, or how
strong they need to be.
• Neutralizing Antibody: Difficult to generate
broadly neutralizing antibodies.
• Vaccine Testing: Slow process, very
expensive
…but on the Brightside…
Precedent from other systems: Success
against other viral infections
Precedent from animal studies: Long-
term control of infection in vaccinated
monkeys
Immune control of HIV-1: Infected
individuals control infection
Vaccine Trials: In progress
Status of HIV Vaccine
Development
Over 60 Phase I/II trials of 30 candidate
vaccines
United States, Thailand, South Africa,
Brazil
One Phase III trial
VaxGen gp120 protein subunit vaccine
CDC collaborating the research
on Vaccine for HIV infection
CDC played an important role in the trials (VAX003 and
VAX004) that evaluated the efficacy of gp120-based
vaccine candidates. VaxGen, which also sponsored the
trials. CDC sponsored a series of behavioural and
biomedical studies linked to the VAX004 efficacy trial in
North America and was part of the consortium that
conducted the VAX003 trial in Thailand. Although the
vaccine candidates failed to prevent HIV infection, the
successful conduct of these trials proved that large HIV
vaccine efficacy trials were possible, even in developing
countries.
Difference between a preventive
HIV vaccine and a therapeutic
HIV vaccine?
Therapeutic HIV vaccines are designed to
control HIV infection in people who are
already HIV positive Preventive HIV
vaccines are designed to protect HIV
negative people from becoming infected
or getting sick. This fact sheet focuses on
preventive HIV vaccines.
Malaria Vaccines in
Progress
Vaccine trails in Malaria
More than a dozen
vaccine candidates
are now in clinical
development, and
one, GlaxoSmithKline
Biologicals’ RTS,S, is
in Phase III clinical
testing—the first
malaria vaccine
candidate to advance
third stage of testing
Phase III trial in Malaria
Phase III trial of the
world’s most clinically
advanced malaria
vaccine candidate was
launched in Kisumu,
Kenya, in July 2009,
under the auspices of the
Kenya Medical Research
Institute (KEMRI)/CDC
Research and Public
Health Collaboration.
Vaccine Candidate—
GlaxoSmithKline Biological
The vaccine candidate—GlaxoSmithKline
Biological' (GSK Bio) RTS,S—is the first of the
current generation of malaria vaccines to
warrant Phase III testing on this scale. The
vaccine has a promising safety profile, was more
than 50% effective in reducing episodes of
clinical malaria in children 5 to 17 months old in
earlier testing, and can be administered together
with the package of vaccinations routinely given
to African children.
Very young taken for trails in view of
High mortality and Morbidity
Phase III trial will
demonstrate how the
vaccine performs in two
groups of children—one
aged 6 to 12 weeks and a
second aged 5 to 17
months—in different
transmission settings
across a wide geographic
region in Africa.
Malaria Vaccine possible in next
few years
In Phase II testing,
the vaccine reduced
cases of malaria in
young children 5 to 17
months by 53%. If
Phase III results are
as good, the vaccine
could be fully
available in the next 5
- 10 years.
DNA Vaccines
DNA Vaccines
DNA vaccines are at
present experimental,
but hold promise for
future therapy since
they will evoke both
Humoral and Cell-
mediated immunity,
without the dangers
associated with live
virus vaccines.
What are DNA Vaccines?
From Scientific
American, July 1995
Making DNA Vaccines
The gene for an antigenic determinant of a
pathogenic organism is inserted into a plasmid.
This genetically engineered plasmid comprises
the DNA vaccine which is then injected into the
host. Within the host cells, the foreign gene can
be expressed (transcribed and translated) from
the plasmid DNA, and if sufficient amounts of the
foreign protein are produced, they will elicit an
immune response
Genetic Engineering a great tool
in developing newer vaccines
It is possible, using genetic engineering, to introduce
a gene coding for an immunogenic protein from one
organism into the genome of another (such as
vaccinia virus). The organism expressing a foreign
gene is called a recombinant. Following injection into
the subject, the recombinant organism will replicate
and express sufficient amounts of the foreign protein
to induce a specific immune response to the protein.
Genetically Engineered
Vaccines a future tool
DNA vaccination is a technique for protecting
an organism against disease by injecting it with
genetically engineered DNA to produce an
immunological response. Nucleic acid vaccines
are still experimental, and have been applied to
a number of viral, bacterial and parasitic models
of disease, as well as to several tumour models.
DNA vaccines have a number of advantages
over conventional vaccines, including the ability
to induce a wider range of immune response
types.
DNA Vaccines are 3 rd
Generation vaccines
DNA vaccines are third generation
vaccines, and are made up of a small,
circular piece of bacterial DNA (called a
plasmid) that has been genetically
engineered to produce one or two specific
proteins (antigens) from a micro-organism.
The vaccine DNA is injected into the cells
of the body, where the "inner machinery"
of the host cells "reads" the DNA and
converts it into pathogenic proteins.
Advantages of DNA Vaccines
Over Other Types of Vaccines
cheaper and easier to produce
safer
can elicit antibody and cellular immune
responses
stable at a broad range of temperature (no
cold-chain requirement)
can be designed and produced by genetic
engineering to have only the desired antigens
or antigenic sequences (epitopes) in the
vaccine
The New GMO Swine Flu
Corn Flakes
Iowa State University
researchers are putting
flu vaccines into the
genetic makeup of corn,
which may someday
allow pigs and humans
to get a flu vaccination
simply by eating corn
or corn products.
WHO Initiative for Vaccine
Research (IVR)
The WHO Initiative for Vaccine Research
was established in 2001 to streamline the
various vaccine research and
development projects being carried out by
different departments of WHO (including
the Special Programme for Research and
Training in Tropical Diseases: TDR) and
UNAIDS.
Importance Of Vaccines For
Adults
Most effective strategies for preventing
illness
Deaths from VPD still occur
Viewed as routine for children and
travelers but not for adults
Make immunizations integral part of
patient care
Why we should support
vaccination
We don't vaccinate just to protect our children.
We also vaccinate to protect our grandchildren
and their grandchildren. With one disease,
smallpox, we "stopped the leak" in the boat by
eradicating the disease. Our children don't have
to get smallpox shots any more because the
disease no longer exists. If we keep vaccinating
now, parents in the future may be able to trust
that diseases like polio and meningitis won't
infect, cripple, or kill children.
Vaccine Controversies
The public health benefits of vaccinations
are exaggerated. Critics of vaccination
policy point out that the mortality rates of
some illnesses were already dramatically
reduced before vaccines were introduced,
and claim that further reductions cannot
immediately be attributed to vaccines.
Secondary and long-term effects on the
immune system from introducing
immunogens directly into the bloodstream
are not fully understood.
Vaccine Controversies
Vaccinations contain chemical
components that are known to be
toxic, such as formaldehyde,
aluminum in various compounds,
acetone, glyceride, ethylene glycol,
and neomycin when injected in large
enough quantities
Can some vaccines cause
Cancers ?
Some researchers
hypothesize possible
links between the
increasing incidence of
cancer and use of
vaccines, suggesting
links to the way
vaccines may alter the
cells in our bodies.
Vaccine development
A Complex Research
Vaccine development for emerging and re-
emerging diseases is a complex issue
There are many mechanisms already in place to
help deal with the development of preventive
vaccines for emerging and re-emerging diseases
Close communication between the Sponsor and
the Agency will hopefully aid in more efficient
product development
Vaccines Can Contain Dangerous
Ingredients Not Adequately Reported to
the Public ?
Public do challenge the safety of
Several Vaccines
Anti-vaccine lobbyists
Not everybody believes that vaccines are good
Despite the ridiculousness of anti-vaccine
arguments, there are significant and influential
followers
They can bring untold damage to immunization
programs and cause diseases and deaths
• Recent examples
– Northern Nigeria and polio
– MMR and measles in UK
– Hepatitis B in India
All the New Vaccines are Under
Scanner by Health Authorities and
Social Activists
Luc Montagnier on Vaccine
for AIDS
Our goal is not to
completely eradicate the
infection - that would be
very difficult - but to
produce a vaccine that
will prevent not infection
but disease. I think this is
more possible.
It's clear that prevention
will never be sufficient.
That's why we need a
vaccine that will be
safe.
Are we getting the Vaccines
in TIME
Created for Dr.T.V.Rao MD’s
‘e’ learning Programme
Email
doctortvrao@gmail.com